Unpublished data submitted in the request demonstrated DT22669 was 1.5 times more effective as an inhibitor of IL-12 signaling than LSF, mimicked LSF insulin-stimulatory effect in human islet cells in the presence of a cocktail of cytokines as well as in the presence of IL-12 alone, restored MTT metabolism, suppressed STAT4 phosphorylation in isolated treated NOD splenocytes in vivo, and prevented T1D in the NOD mouse. Here, STAT4 is linked to type 1 diabetes mellitus.